期刊文献+

CK19和Galectin-3在鉴别甲状腺良恶性肿瘤中的应用价值 被引量:3

DIAGNOSTIC VALUE OF GALECTIN-3 AND CK19 IN BENIGN OR MALIGNANT THYROID TUMOR
原文传递
导出
摘要 目的探讨CK19和Galectin-3在鉴别甲状腺良恶性肿瘤中的应用价值。方法应用免疫组织化学EnVision法检测CK19和Galectin-3蛋白在甲状腺乳头状癌、甲状腺腺瘤、结节性甲状腺肿和桥本甲状腺炎中的表达。结果CK19和Galectin-3蛋白在甲状腺乳头状癌、甲状腺腺瘤、结节性甲状腺肿和桥本甲状腺炎中的阳性表达率分别为97.9%、6.7%、5.6%、46.7%和100.0%、26.7%、16.7%和93.3%。结论CK19和Galectin-3蛋白在甲状腺乳头状癌与甲状腺腺瘤、结节性甲状腺肿鉴别诊断中具有较高的应用价值,而对甲状腺乳头状癌与桥本甲状腺炎的鉴别诊断受到限制。 t Objective To study the diagnostic value of combination detection with galeetin- 3 and CK19 in benign or malignant thyroid tumor. Methods Immunohistochemistry (envision method) was employed to detect the expression of galectin- 3 and CK19 protein in benign or malignant thyroid tumor. Results The positive rate of galectin- 3 and CK19 protein in thyroid papillary carcinoma, thyroid follicular adenoma, nodular goiter and Hashimoto's thyroiditis were 97.9%, 6.7%, 5.6%, 46.7% and 100%, 26.7%, 16.7%, 93.3%, respectively. Conclusion CK19 and galectin-3 are important markers in distinguishing thyroid papillary carcinoma with thyroid follicular adenoma, nodular goiter, but restricted in Hashimoto's thyroiditis.
出处 《中国煤炭工业医学杂志》 2009年第12期1847-1848,共2页 Chinese Journal of Coal Industry Medicine
关键词 CK19 GaIectin-3 甲状腺肿瘤 免疫组织化学 鍪别诊断 CK19 galectin-3 thyroid carcinoma immunohistochemistry differential diagnosis
  • 相关文献

参考文献8

  • 1Schelfhout LJ, Van Muijen GN, Fleuren GJ. Expression of keratin 19 distinguishes papillary thyroid carcinoma from follicular carcinomas and follicular thyroid adenoma[J].Am J Clin Pathol,1989,13:1034- 1040.
  • 2Casey MB, Lohse CM, Lloyd RV. Distinction between papillary thyroid hyperplasia and papillary thyroid carcinoma by inmunohistochemical staining for cytokeratin 19, galectin - 3, and HBMI- 1[J].Endoer Pathol,2003,14(1) :5 - 60.
  • 3黄悦,赵建华,樊克武.HBME-1和CK19、Galectin-3在甲状腺乳头状癌中表达及诊断价值[J].南京医科大学学报(自然科学版),2007,27(11):1294-1297. 被引量:13
  • 4张静,王莉.CK19、RET、Survivin在甲状腺乳头状癌及淋巴细胞性甲状腺炎中表达的意义[J].新疆医科大学学报,2008,31(9):1154-1155. 被引量:2
  • 5David C,Kilpatrick. Animal lectins: a historical introduction and overview[J]. Biochimica et Biophysics Acta, 2002,1572 : 187 - 197.
  • 6Xu XC, Naggar AK, Lotan R. Differential expression of galcctin - 1 and galcctin - 3 in thyroid tumors. Potential diagnostici implications[J]. Am J Palhol,1995,47(3) :815.
  • 7Coli A, Bigotti G, Zucchetti F, et al. Galectin- 3, a marker of well-differentiated thyroid carcinrma is expressed in thyroid nodules with cytological atypic[J].Histopathology, 2002,40 (1) :80 - 87.
  • 8郑璐滢,朱建善,王家东,许雁萍.Galectin-3、CK19和TPO表达在甲状腺良恶性肿瘤病理诊断中的价值[J].临床与实验病理学杂志,2005,21(4):449-453. 被引量:18

二级参考文献36

  • 1赵延龙,陈江,姜汉国.Survivin、p53基因在甲状腺乳头状癌组织中表达的研究[J].哈尔滨医科大学学报,2006,40(1):23-26. 被引量:9
  • 2徐少明,王平,李祖栋.桥本氏病并发甲状腺癌[J].中华外科杂志,1996,34(7):424-426. 被引量:70
  • 3方海飞,沈美萍,徐银峰.甲状腺乳头状癌TGF-β_1、CD_(31)表达与肿瘤转移的关系[J].南京医科大学学报(自然科学版),2007,27(5):472-475. 被引量:16
  • 4Fonseca E, Nesland JM, Hoie J, et al. Pattern of expression of intermediate cytokeratin filaments in the thyroid gland: an immunohistochemical study of simple and stratified epithelial-type cytokeratins[J]. Virchows Arch, 1997,430(3):239-45.
  • 5Ghali VS, Jimenez EJ, Garcia RL. Distribution of leu-7 antigen (HNK-1) in thyroid tumors: its usefulness as a diagnostic marker for follicular and papillary carcinomas[J]. Hum Pathol, 1992,23(1): 21-5.
  • 6Barondes SH, Castronovo V, Cooper DN, et al. Galectins: a family of animals β-galectaside-binding lectins[J]. Cell, 1994,76(4): 597-8.
  • 7Inohara H, Raz A. Functional evidence that cell surface galectin-3 mediate homotypic cell adhesion[J]. Cancer Res,1995,55(15): 3267-71.
  • 8Castronovo V, Van Den Brule FA, Jackers P, et al. Decreased expression of galectin-3 is associated with progression of human breast cancer[J]. J Pathol,1996,179(1): 43-8.
  • 9Baldus SE, Zirbes TK, Weingarten M, et al. Increased galectin-3 expression in gastric cancer: correlations with histopathological subtypes, galactosylated antigens and tumor cell proliferation[J]. Tumour Biol,2000,21(5): 258-66.
  • 10Xu XC, el-Naggar AK, Lotan R. Differential expression of galectin-1 and galectin-3 in thyroid tumors. Potential diagnostic implications[J]. Am J Pathol,1995,147(3): 815-22.

共引文献28

同被引文献19

  • 1Davies H,Bignell GR,Cox C,et al.Mutations of the BRAFgene in human cancer[J].Nature,2002,417(6892):949-954.
  • 2Jean Jacques Michels,Marnay Jacques,Michel Henry-Amar,et al.Prevalence and prognostic significance of tall cell variant of papillary thyroid carcinoma[J].Human Pathology,2007,38(2):212-219.
  • 3Peter M.Sadow,Jennifer L.Hunt.Update on clinically important variants of papillary thyroid carcinoma[J].Diagnostic Histopathology,2011,17(3):106-113.
  • 4Andrew J.Gaudena,Stanislaw J.Gaudenb.Multiple cerebral metastases as a primary presentation in papillary thyroid carcinoma[J].Journal of Clinical Neuroscience,2010,17(3):379-380.
  • 5Shin E,Chung WY,Yang WI,et al.RET/PTC and CK19 expression in papillary thyroid carcinoma and its clinicopathologic correlation[J].J Korean Med Sci,2005,20(1):98-104.
  • 6Sawangareetrakul P,Srisomsap C,Chokchaichamnankit D,et al.Galectin-3 expression in human papillary thyroid carcinoma[J].Cancer Genomics Proteomics,2008,5(2):117-22.
  • 7Dongbin Ahna,June Sik Parka,Jin Ho Sohn,et al.BRAFV600E mutation does not serve as a prognostic factor in Korean patients with papillary thyroid carcinoma[J].Auris Nasus Larynx,2011,7(11):1016.
  • 8黄悦,赵建华,樊克武,等.HMBE—l,CKl9,Galectin-3在甲状腺乳头状癌中的表达及诊断价值.南京医科大学报,2007,(11):1294.
  • 9王春玲,胡小萍.免疫组化在甲状腺癌中表达的临床病理分析[J].中国社区医师(医学专业),2008,10(15):156-156. 被引量:2
  • 10牛卫,罗月球,陈丽荣.甲状腺乳头状癌BRAF基因突变及表达的临床意义研究[J].实用肿瘤杂志,2008,23(6):519-523. 被引量:11

引证文献3

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部